Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

61.23
Delayed Data
As of Dec 09
 +1.11 / +1.85%
Today’s Change
47.97
Today|||52-Week Range
65.46
+15.92%
Year-to-Date
MRK Regular Dividend: MRK will begin trading ex-dividend on 12/13/16 with a $0.47 dividend payable to shareholders of record as of 12/15/16.
Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly
4:34pm / GuruFocus News - Paid Partner Content
The Zacks Analyst Blog Highlights: MasterCard, Merck, Cisco and Visa
Dec 08 / Zacks.com - Paid Partner Content
3 Big Advances In Cancer Treatment In 2016
2:08pm / MotleyFool.com - Paid Partner Content
Top Research Reports for Cisco, Merck & MasterCard
Dec 07 / Zacks.com - Paid Partner Content
The 3 Fastest-Growing Drug Classes Over the Next 5 Years
11:44am / MotleyFool.com - Paid Partner Content
Why AstraZeneca plc Stock Slumped in November
Dec 07 / MotleyFool.com - Paid Partner Content
Should Big Pharma Be Worried About a Trump Trade War?
6:50am / MotleyFool.com - Paid Partner Content
Lilly: Jardiance Label to Add Cardiovascular Indication
Dec 06 / Zacks.com - Paid Partner Content
US Market Indexes End the Week Higher
Dec 09 / GuruFocus News - Paid Partner Content
Intermediate Trade: Merck
Dec 06 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close60.12
Today’s open60.49
Day’s range60.40 - 61.51
Volume10,516,352
Average volume (3 months)10,826,890
Market cap$168.8B
Dividend yield3.07%
Data as of 4:00pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)-61.67%
Earnings growth (this year)+5.11%
Earnings growth (next 5 years)+6.00%
Revenue growth (last year)-7.92%
P/E ratio31.2
Price/Sales3.87
Price/Book3.81

Competitors

 Today’s
change
Today’s
% change
NVSNovartis+2.15+3.18%
PFEPfizer+0.76+2.46%
SNYSanofi+0.63+1.58%
ABBVAbbVie+0.64+1.05%
Data as of 4:02pm ET, 12/09/2016

Financials

Next reporting dateFebruary 8, 2017
EPS forecast (this quarter)$0.89
Annual revenue (last year)$38.8B
Annual profit (last year)$4.4B
Net profit margin11.46%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chairman, President &
Chief Executive Officer
Kenneth C. Frazier
Chief Financial Officer &
Executive Vice President
Robert M. Davis
Corporate headquarters
Kenilworth, New Jersey

Forecasts


Search for Jobs